AUTHORS
Jodi Forward, MD, William Tyler Frantz, MD-PhD2, Lahari Uppuluri, PhD3, Kadriye Nehir Cosgun, PhD4, Mark E Robinson, PhD5, David T. Teachey, MD6, Markus Müschen, MD-PhD7
AFFILIATIONS
1 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Pediatrics, Section of Hematology-Oncology, New Haven, Connecticut, United States
2 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States, Department of Pediatrics, Section of Hematology-Oncology, New Haven, Connecticut, United States
3 Division of Oncology and Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States
4 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
5 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
6 Division of Oncology and Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States
7 Center of Molecular and Cellular Oncology, New Haven, Connecticut, United States
ABSTRACT
Background and Significance: T-cell acute lymphoblastic leukemia (T-ALL) is a biologically heterogeneous, high-risk malignancy arising in both children and adults. The transcription factor lymphoid enhancer binding factor 1 (LEF1) is a central nuclear effector of Wnt/β-catenin signaling and is recurrently altered in T-ALL, yet the genomic architecture and clinical implications of specific LEF1 alterations remain incompletely defined. LEF1 contains an N-terminal β-catenin-binding domain, encoded by exons 1-3, and a C-terminal high-mobility group DNA-binding domain. Our group has shown that, unlike solid tumors in which β-catenin drives oncogenic WNT-signaling, lymphoid cells depend on high-efficiency β-catenin protein degradation for survival. In B- and T-cell malignancies, nuclear β-catenin-LEF1 complexes repress MYC and trigger leukemic cell death (Cosgun et al., Nature Cancer 2026). Although LEF1 inactivating events have been reported in T-ALL, the copy-number and structural landscape of LEF1, and its prognostic relevance in a large, uniformly treated pediatric cohort, have not been systematically analyzed.
Results: We performed comprehensive genomic annotation of 1,335 pediatric T-ALL cases enrolled on the Children’s Oncology Group trial AALL0434 using publicly available whole-genome sequencing data. We integrated copy-number, structural-variant, and single-nucleotide-variant data to classify LEF1 status as wild-type, focal exon 2-3 alteration, or other LEF1 alteration, and mapped structural breakpoints to define the extent of the deleted region. We correlated alteration class with immunophenotype (ETP, near-ETP, and non-ETP), genomic subtype, presenting clinical features, day 29 minimal residual disease (MRD), and event-free (EFS) and overall survival (OS). Cases not meeting focal exon 2-3 criteria, but harboring LEF1 sequence variants or broader copy-number loss were grouped as other LEF1 alterations. Focal intragenic LEF1 exon 2-3 lesions were identified in a substantial subset of non-ETP T-ALL (169/863, 19.6%) but were absent in ETP T-ALL (0/110) and rare in near-ETP cases (1/168, 0.6%), restricting them to more mature immunophenotypes. Focal alterations affecting exons 2-3, which encode the β-catenin-binding domain, comprised 83.6% of total LEF1-altered cases with strikingly conserved breakpoint regions. Breakpoints clustered within two narrow hotspots in introns 1 and 3, each immediately adjacent to a cryptic recombination signal sequence heptamer in convergent orientation with N- and P-nucleotides inserted within the junction, a hallmark of recombination-activating genes 1 and 2 (RAG1/2) activity. These features suggest that intragenic LEF1 exon 2-3 lesions arise from off-target RAG1/2-mediated recombination, explaining their recurrence and restriction to RAG1/2-active non-ETP subtypes. Gene expression analysis demonstrated that patients with focal exon 2-3 alterations retained high LEF1 expression supporting preservation of LEF1 transcription rather than complete gene loss. LEF1-altered cases were significantly enriched within the TAL1, TLX, and NKX2-1 genomic subtypes. Within these subtypes, LEF1 exon 2-3 alterations were associated with hyperleukocytosis (WBC > 50 x 10^9/L) at diagnosis (OR 2.0, P= 0.002) and, paradoxically, with improved day 29 MRD clearance (OR 0.28, P< 0.0001), with no significant differences in CNS status, EFS, or OS between altered and wild-type cases.
Conclusions: Focal LEF1 alterations in childhood T-ALL are subtype-restricted, non-random structural events that preferentially disrupt the N-terminal β-catenin-binding domain while sparing the DNA-binding domain. These lesions are entirely absent in T-ALL subtypes with earlier developmental arrest such as ETP. Intragenic focal deletions within LEF1 in patients with T-ALL reflect off-target RAG activity as previously described for IKZF1 in B-ALL. LEF1 exon 2-3 lesions mark a biologically distinct subset defined by cortical subtypes, high presenting leukocyte burden, and, paradoxically, superior early treatment response as reflected by markedly improved day 29 MRD clearance. Although this favorable early response did not translate into a measurable EFS or OS advantage in this cohort, the MRD signal suggests possible differences in chemosensitivity that warrant mechanistic study.
DISCLOSURES
Jodi Forward, MD: No relevant conflicts of interest to declare.